tetano
Editor, Senior Moderator
Sci Adv
. 2024 Mar 8;10(10):eadj6380.
doi: 10.1126/sciadv.adj6380. Epub 2024 Mar 6. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer
Shahad K Alsaiari[SUP] 1 [/SUP], Seba Nadeef[SUP] 1 [/SUP], John L Daristotle[SUP] 1 [/SUP], William Rothwell[SUP] 1 2 [/SUP], Bujie Du[SUP] 1 [/SUP], Johnny Garcia[SUP] 1 [/SUP], Linzixuan Zhang[SUP] 3 [/SUP], Morteza Sarmadi[SUP] 1 [/SUP], Timothy A Forster[SUP] 1 [/SUP], Nandita Menon[SUP] 1 [/SUP], Stacey Qiaohui Lin[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 4 [/SUP], Nicole Hachmann[SUP] 4 [/SUP], Erika Yan Wang[SUP] 1 [/SUP], John D Ventura[SUP] 4 [/SUP], Dan H Barouch[SUP] 4 [/SUP], Robert Langer[SUP] 1 3 [/SUP], Ana Jaklenec[SUP] 1 [/SUP]
Affiliations
Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework-8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.
. 2024 Mar 8;10(10):eadj6380.
doi: 10.1126/sciadv.adj6380. Epub 2024 Mar 6. Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer
Shahad K Alsaiari[SUP] 1 [/SUP], Seba Nadeef[SUP] 1 [/SUP], John L Daristotle[SUP] 1 [/SUP], William Rothwell[SUP] 1 2 [/SUP], Bujie Du[SUP] 1 [/SUP], Johnny Garcia[SUP] 1 [/SUP], Linzixuan Zhang[SUP] 3 [/SUP], Morteza Sarmadi[SUP] 1 [/SUP], Timothy A Forster[SUP] 1 [/SUP], Nandita Menon[SUP] 1 [/SUP], Stacey Qiaohui Lin[SUP] 1 [/SUP], Lisa H Tostanoski[SUP] 4 [/SUP], Nicole Hachmann[SUP] 4 [/SUP], Erika Yan Wang[SUP] 1 [/SUP], John D Ventura[SUP] 4 [/SUP], Dan H Barouch[SUP] 4 [/SUP], Robert Langer[SUP] 1 3 [/SUP], Ana Jaklenec[SUP] 1 [/SUP]
Affiliations
- PMID: 38446889
- PMCID: PMC10917347
- DOI: 10.1126/sciadv.adj6380
Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework-8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.